Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Development History

Past

days

AZNPhase 3$291.4B

Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate Phase 3 Results Expected

Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate• Chronic Obstructive Pulmonary Disease171

Jan 30Estimated

00%

Drug Information

Target Indication

Chronic Obstructive Pulmonary Disease

Clinical Trial

Last updated: 2/9/2026

Developer

AZN

AstraZeneca PLC

Related Pipeline

Irritable Bowel Syndrome With Constipation (IBS-C)

Muscle Invasive Bladder Cancer

Asthma, Exercise-Induced

Affective Psychosis, Bipolar

Carcinoma, Non-Small-Cell Lung